Investor Newsletter

Issue 01 2021

MicroPort®

MicroPort® NeuroTech's U-track Intracranial Support Catheter System Receives NMPA Approval

The U-track Intracranial Support Catheter System, a product developed by Shanghai MicroPort® NeuroTech Co., Ltd. (MicroPort® NeuroTech) for establishing vascular access in neurointerventional procedures, recently received a registration certificate issued by the Chinese National Medical Products Administration (NMPA).

Compared with rival products, MicroPort® NeuroTech's U-track Intracranial Support Catheter System features a larger lumen, easing the delivery of multiple devices, and a rounded tip design for safe tracking through the tortuous vessels to reach the desired neurovascular locations during clinical procedures, while ensuring outstanding support, pushability and buckling resistance. The approval of the U-track Intracranial Support Catheter System marks the further development of the neurointerventional portfolio of MicroPort® NeuroTech.

MicroPort

MicroPort® Coronary Balloon Dilatation Catheter (Firefighter™ NC) Receives Registration Approval in Taiwan China

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) has recently received a medical device license from the Taiwan Ministry of Health and Welfare (MOHW) for its proprietary coronary balloon dilatation catheter, Firefighter™ NC.

The market approval of Firefighter™ NC further broadens the coronary product portfolio of MicroPort® in Taiwan, China. As the Firehawk™ Rapamycin Target Eluting Coronary Stent System, Firefighter™, and the Coronary Balloon Dilatation Catheter (Firefighter™ NC) successively enter the Taiwan market, MicroPort® is gaining influence and market share in the local market. In the future, MicroPort® will continue to expand the Taiwan market and provide local patients and doctors with high quality, universally accessible medical products and services.

MicroPort

Firefighter™ and Foxtrot™ Pro PTCA Balloon Catheters Approved for Registration in Pakistan

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) has recently received registration approval from the Drug Regulatory Authority of Pakistan for its Firefighter™ PTCA Balloon Catheter (Firefighter™) and Foxtrot™ Pro PTCA Balloon Catheter (Foxtrot™ Pro) products.

Designed for coronary dilation through percutaneous transluminal coronary angioplasty (PTCA), MicroPort® Firefighter™ PTCA Balloon Catheter can be used with the company's Firehawk™ Rapamycin Target Eluting Coronary Stent System for lesion dilation before stent implantation. MicroPort® Foxtrot™ Pro PTCA Balloon Catheter is also suitable for lesion dilation before stent implantation in PTCA procedures.

The approval of Firefighter™ and Foxtrot™ Pro has expanded the coronary product offerings of MicroPort® in Pakistan and enables local patients access to a wider range of treatment solutions



MicroPort

Horizon Medical™ Ovum Aspiration Needle Registration Approved in Thailand

The Ovum Aspiration Needle developed by Shanghai Horizon Medical Co., Ltd. Horizon Medical™ has now received registration approval from the Thai Food and Drug Administration (TFDA), making it the first product by Horizon Medical™ to gain approval in overseas markets.

Approved in China during 2019, Ovum Aspiration Needle has been well recognized by experts for its clinical applications ever since. Dr. Guo Zong, Executive Vice President of Horizon Medical™ said, "The registration approval of the Ovum Aspiration Needle in Thailand is a milestone for the future development of Horizon Medical™ in overseas markets. We will continue to innovate our research and development efforts to ensure we can meet the need of as many patients and doctors as possible. This approval helps us to provide improved assisted reproductive technology solutions for more patients and doctors worldwide."



MicroPort

Skywalker™ Total Knee Robot System Completes Multicenter Clinical Trial Enrollment Before Market Launch

Skywalker™, a total knee robot system ("Skywalker™"), independently developed by Suzhou MicroPort OrthoBot Co., Ltd. ("MicroPort® OrthoBot"), a subsidiary of Shanghai Microport Medbot （Group） Co., Ltd. ("MicroPort® MedBot"), recently performed the 100th surgery in its multicenter clinical trial before its commercial launch, marking the successful completion of the project's case enrollment task.

Skywalker™ is a surgical robot to assist in total knee replacements. Its preoperative planning software generates a personalized prosthesis implantation surgical plan based on the patient's preoperative CT scan data, prosthesis model data, and the anatomical characteristics of the patient's lower limb bones. During operations, with the help of the alignment technology, the highly dexterous and lightweight robotic arm can perform precise positioning according to the surgical plan for quick and accurate osteotomy. The system can do without the medullary cavity positioning required by traditional surgery, which reduces surgical injury, improves the postoperative lower limb alignment, reduces surgical complications, and helps patients achieve rapid postoperative recovery.

MicroPort

Toumai™ Endoscopic Robot Completes First Domestic Robot-assisted Single-port Procedure

The Toumai™ Endoscopic Surgery Robotic System (Toumai™ Endoscopic Robot), a proprietary product of Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot), a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), has now completed the first robot-assisted single-port partial nephrectomy at Zhejiang Provincial People's Hospital.

Compared with conventional laparoscopic single-port surgery, the robot-assisted surgery enables the ability to overcome the current constraints, limiting conventional surgical instruments and reverse manipulations that are common in the traditional single-port operations. Furthermore, the accuracy of medical robots is more prominent when they are used in surgeries that require a high level of precision. Surgical results are comparable to those of multiport procedures, while it provides additional benefits such as minimal invasiveness, safety, aesthetics, as well as less postoperative pain and quicker recovery.

Patient Enrollment Completed for Clinical Trial of Toumai™ Endoscopic Robot

On January 27th, 2021, with completion of patient enrollment for clinical trials of the Toumai™ Endoscopic Surgery Robotic System (Toumai™) developed by Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot), a subsidiary of Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), Toumai™ became China's first domestically-manufactured endoscopic robot for multicenter clinical trials in the field of urology.

During the enrollment period, Toumai™ had already assisted clinical experts to make breakthroughs and reach milestones of significant clinical value by overcoming ever-increasing surgical challenges to complete a number of difficult urological surgeries, including the first domestic robot-assisted radical prostatectomy, partial nephrectomy, and retroperitoneal approach to partial nephrectomy. The success has proved the technical strength of China's independently developed endoscopic surgical robots to assist with complex surgeries in narrow anatomical space, and it has also filled the gap in China regarding domestically developed innovative medical solutions for this field.





MicroPort

MicroPort® Holds a Symposium on Firehawk™ Clinical Progress at Taiwan Transcatheter Therapeutics

The annual Taiwan Transcatheter Therapeutics (TTT) meeting was held from January 9-10, 2021 at the International Conference Center of National Taiwan University Hospital in Taipei, China. Due to the impacts of COVID-19, TTT 2021 was held as an online-offline hybrid event, gathering participants from all over the world to virtually participate at the main venue in Taipei for an in-depth exchange of updates on the current development and clinical needs in the field of percutaneous coronary intervention (PCI) in their respective countries.

During TTT 2021, Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") held a satellite symposium on the clinical progress of the Firehawk™ Rapamycin Target Eluting Coronary Stent System (Firehawk™), where three professors from Beijing, Hong Kong and South Korea shared their clinical experiences of Firehawk™ and recent clinical research studies.

The online symposium not only brought to light the wide application of the Firehawk™ Stent in different lesions, but also promoted academic exchanges in cardiology between experts in Beijing, Hong Kong, and South Korea. In addition, experts and professors from different countries and regions contributed their valuable experience to the body of knowledge on coronary intervention therapy by sharing their own clinical trials and studies. In the future, MicroPort® will continue to take an active part in worldwide academic exchange, and remain dedicated to benefiting more patients suffering from cardiovascular diseases.

MicroPort

MicroPort® Wins First Prize of Shanghai Innovative Achievement Award for Modernized Enterprise Management for the Second Consecutive Year

The project "Governance improvement and operational synergy practices under MAH policy," led by Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®), won the first prize of the Shanghai Innovative Achievement Award for Modernized Enterprise Management for 2020. The award, announced by the Review Committee on December 25, 2020, marks the second consecutive year that MicroPort® has been awarded first prize, following its project "Brand building and management of large-scale high-end medical device enterprises" in 2019.

As part of their "Governance improvement and operational synergy practices under MAH policy" project, MicroPort® developed the "Speed Dial Management" model – a standardized, implementable and replicable interactive management model for medical device registrants. Additionally, the project identified the core philosophy of "synergy through three parties, three guidelines and three flows," which is a significant experience for promoting and implementing the MAH policy within the medical device industry.

Investor Newsletter

Issue 01 2021

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com